What Is the Best Weight Loss Medication on the Market?

Tirzepatide, sold as Zepbound for weight management, currently produces the largest average weight loss of any approved medication, outperforming both semaglutide (Wegovy) and liraglutide (Saxenda) in head-to-head network analyses. But the “best” medication for any individual depends on more than raw pounds lost. Tolerability, insurance coverage, how the drug is taken, what happens after stopping, and a growing list of benefits beyond the scale all shape the real-world answer in ways that a simple ranking cannot capture.

How the Leading Medications Stack Up

Two large network meta-analyses, each pooling data from randomized controlled trials, put tirzepatide at the top for weight reduction in people without type 2 diabetes. At the 15 mg dose, tirzepatide produced roughly 14 percent more weight loss than liraglutide and about 6 percent more than semaglutide 2.4 mg when compared indirectly through shared placebo arms.¹ A separate systematic review confirmed tirzepatide 15 mg ranked highest for both weight and waist-circumference reduction, while liraglutide consistently produced the smallest losses among the newer agents.²

Phentermine/topiramate (Qsymia), one of the older combination drugs still on the market, sits well below the newer injectables. A meta-analysis found average weight loss of about 8 kg at the highest dose compared to placebo, with lower doses producing less.³ That matters if you cannot access or tolerate the injectable drugs, but it is a different league of weight loss. Orlistat (Alli/Xenical) and naltrexone/bupropion (Contrave) produce even more modest results and are generally considered second-line options today.

Why Tirzepatide Works Differently

The newer weight loss medications all belong to a family that mimics a gut hormone called GLP-1. When you eat, your intestine naturally releases GLP-1, which signals your brain to feel full, slows the rate your stomach empties, and helps regulate blood sugar. Semaglutide and liraglutide are synthetic versions of this hormone, engineered to last much longer in the body than the natural form.

Tirzepatide goes a step further. It activates two hormone receptors instead of one: GLP-1 and GIP. That dual action appears to enhance energy regulation through additional pathways, which helps explain the extra weight loss seen in trials.⁴ Researchers are already testing triple-receptor agonists like retatrutide, which add a third target (the glucagon receptor), in hopes of pushing the ceiling even higher.

One of the more striking effects patients describe is a quieting of what many call “food noise,” the constant background chatter of cravings and food-related thoughts. Early neuroimaging research suggests these drugs may reduce the brain’s reward response to food cues, making it easier to pass up temptation without relying purely on willpower.⁵ That research is still preliminary, but it aligns with what millions of patients report anecdotally.

The Side-Effect Picture

Nausea is the price of entry for nearly every GLP-1-based medication. A large network meta-analysis of over 33,000 patients found that all evaluated GLP-1 drugs significantly increased nausea risk, with tirzepatide and semaglutide both ranking high. Vomiting, diarrhea, and constipation round out the list of common complaints.⁶ These symptoms are the single biggest reason people quit treatment, and they tend to be worst during dose escalation.⁷

Phentermine/topiramate has its own distinct set of problems: altered taste, tingling or numbness in the extremities, dry mouth, trouble concentrating, and irritability were all significantly more common than with placebo.³ Topiramate also carries risks during pregnancy, which limits its use in women of childbearing age.

Rarer but more serious gastrointestinal events deserve mention. A study using insurance claims data found that GLP-1 agonists were associated with higher rates of pancreatitis, bowel obstruction, and gastroparesis compared to another weight loss drug (naltrexone/bupropion).⁸ A more recent meta-analysis of randomized trials found an increased risk of gallstones and acid reflux but no significant increase in most other serious gastrointestinal or biliary events.⁹ Another large matched-cohort study in people with type 2 diabetes found elevated gastroparesis risk but no significant difference in pancreatitis or gallbladder disease rates.¹⁰ The inconsistency across study designs is worth noting: the absolute risk of these rare events remains low, but they are not zero.

Weight Regain After Stopping

This is the part the marketing material glosses over. When participants in the STEP 1 trial stopped semaglutide, they regained about two-thirds of the weight they had lost within a year. Net weight loss from the start of the study shrank from about 17 percent to roughly 6 percent once the drug was withdrawn.¹¹ The cardiometabolic improvements that came with weight loss, such as better blood pressure and cholesterol, also drifted back toward baseline.

A Bayesian meta-analysis that pooled data from discontinuation studies of both semaglutide and tirzepatide estimated regain at about 1 kg per month after stopping, with half the initial weight loss recovered in roughly seven to eight months. At that rate, full return to baseline weight was projected by about 15 months.¹² This does not mean the drugs fail. It means obesity increasingly looks like a condition requiring ongoing treatment, much like high blood pressure or high cholesterol. The drug works while you take it. That reality raises obvious questions about cost, access, and commitment that anyone considering these medications needs to think through honestly.

Benefits That Go Beyond the Scale

One of the most consequential shifts in how doctors view these drugs is the evidence for cardiovascular protection. A meta-analysis found that GLP-1 and dual-receptor agonists reduced the risk of major cardiovascular events by about 13 percent, all-cause mortality by about 12 percent, and death from heart disease by a similar margin compared to placebo.¹³ A separate meta-analysis focused on people with obesity found GLP-1 drugs significantly reduced heart attacks specifically, cutting risk by about 28 percent.¹⁴

The list of conditions these drugs appear to help keeps growing. Clinical trials have now shown benefits for heart failure with preserved ejection fraction, fatty liver disease (including reduced fibrosis), obstructive sleep apnea, and knee osteoarthritis.¹⁵ GLP-1 drugs have also shown significant improvement in biochemical and tissue markers of fatty liver disease.¹⁶ These broader benefits are a major reason the medical community’s attitude toward weight loss drugs has shifted so dramatically. For someone with obesity-related heart disease or liver problems, the medication may be justified by its cardiovascular or metabolic effects alone, not just the number on the scale.

Fat Loss Versus Muscle Loss

A common concern is that rapid weight loss from these drugs chews through muscle along with fat. Data from the SURMOUNT-1 trial showed that tirzepatide users lost about 21 percent of their body weight over 72 weeks, and roughly 75 percent of what they lost was fat mass while 25 percent was lean mass.¹⁷ That 75/25 split is actually consistent with what happens during any major calorie deficit, including diet and exercise alone or even bariatric surgery. The placebo group showed the same ratio. So the drugs do not seem to cause disproportionate muscle wasting, but losing a quarter of a large amount of weight as lean tissue is still meaningful, especially for older adults. Resistance training while on medication is widely recommended, though no large trial has formally tested the combination yet.

How Medications Compare to Bariatric Surgery

Bariatric surgery remains the most powerful weight loss intervention available. A study comparing over 1,500 patients found that surgery produced average total weight loss of about 28 percent over two years, compared to about 10 percent with GLP-1 drugs.¹⁸ A systematic review looking across more outcomes confirmed surgery’s superiority for sustained weight loss, diabetes remission, and cardiovascular risk reduction. Tirzepatide at its highest dose approached but did not match the weight loss produced by sleeve gastrectomy at 72 weeks, and surgical patients maintained their results better long-term because there is no “stopping” a surgery.¹⁹

That said, surgery carries its own risks, requires recovery time, and is irreversible. Many patients prefer a less invasive first step. The emerging reality is that some people may eventually combine surgery and medication for maximum benefit, while others may find the drugs are enough on their own.

Real-World Persistence Is Far Lower Than Trial Completion

Clinical trials have motivated participants, free medication, and regular follow-up. Real life is different. Among commercially insured adults using GLP-1 drugs for obesity, only about 32 percent were still filling prescriptions at one year. Semaglutide had the best retention at about 47 percent, while liraglutide lagged at roughly 19 percent.²⁰ A cohort study within an integrated health system found that patients who stuck with semaglutide for a full year lost about 14 percent of their body weight, while those who did not stay on it lost roughly 6 percent.²¹ Side effects, cost, and supply shortages all drive people off treatment. The gap between what these drugs can do in a trial and what they actually achieve in practice is substantial.

Cost, Coverage, and Access Barriers

The list prices of the newer injectable medications run over $1,000 per month without insurance, and coverage varies wildly. Many insurers and most state Medicaid programs historically excluded weight loss drugs from formularies, though this is slowly changing as cardiovascular data strengthen the case for coverage. Research has documented significant disparities in who gets prescribed these medications and who actually fills those prescriptions, driven by insurance type and patient demographics.²² Access is arguably the single biggest practical barrier to using what works best on paper. A medication that produces 20 percent weight loss in trials is not “the best” for someone who cannot get it or cannot afford to stay on it long enough for it to work.

Mental Health Effects Are Still Unsettled

The relationship between GLP-1 drugs and mental health is one of the more confusing areas in the current research. A systematic review and meta-analysis found no evidence that GLP-1 drugs worsen depression compared to placebo, and found moderate improvements in eating-related behaviors like emotional eating and eating restraint. Quality of life improved across multiple domains, and those improvements appeared to happen independently of how much weight people lost.²³

Yet a large observational study found higher rates of depression, anxiety, and suicidal ideation among GLP-1 users compared to non-users over time.²⁴ Observational studies like this cannot prove causation: people prescribed weight loss drugs may have had higher baseline rates of psychiatric conditions, or the experience of rapid body change itself may contribute. The randomized trial evidence is more reassuring, but regulatory agencies continue to monitor the signal. If you are starting one of these drugs and have a history of depression or anxiety, that context matters for your care plan.

Adolescents and Younger Patients

The pediatric landscape is more limited. Liraglutide was the first GLP-1 drug approved for adolescents aged 12 and older with obesity, producing modest BMI reductions compared to placebo over 56 weeks.²⁵ Semaglutide has since gained FDA approval for the same age group, with stronger weight loss data. Post hoc analyses suggest adolescents respond to liraglutide regardless of sex, race, or obesity severity, and that early responders tend to do best at the end of treatment.²⁶ Gastrointestinal side effects are more common in adolescents than in the placebo group, and long-term safety data in growing bodies remain limited.

What Is Coming Next

The pipeline for obesity drugs is busier than it has ever been. Oral semaglutide already exists for diabetes, and higher-dose oral formulations for obesity are either approved or in late-stage trials. The oral version uses a special absorption-enhancing compound to survive the stomach, but its bioavailability is lower and more variable than the injected form, often requiring higher doses to match the same effect.²⁷ Still, a pill instead of a weekly injection would eliminate a significant barrier for many patients.

CagriSema, a combination of semaglutide and cagrilintide (an amylin analogue), is in phase 3 trials and looks to push weight loss beyond what semaglutide alone achieves. Early data showed it produced roughly 9 percentage points more weight loss than semaglutide 2.4 mg alone over 20 to 32 weeks.²⁸ Triple-receptor agonists like retatrutide, targeting GLP-1, GIP, and glucagon receptors simultaneously, are also in trials and have produced striking weight loss numbers in early phases. Whether these next-generation drugs maintain their advantage once tested in larger, longer studies remains to be seen.

The Troubled History That Shaped Today’s Standards

The current generation of weight loss drugs exists in the shadow of a grim track record. Over the past several decades, multiple obesity medications were pulled from the market after causing serious harm. Aminorex triggered a wave of fatal pulmonary hypertension. The fen-phen combination (fenfluramine-phentermine) caused heart valve damage. Phenylpropanolamine raised stroke risk. Sibutramine was withdrawn for excess cardiovascular events. Rimonabant, approved in Europe but rejected in the United States, was pulled after psychiatric side effects including suicidality.²⁹³⁰ A systematic review found that psychiatric disturbances, heart toxicity, and addiction together accounted for more than four out of five post-marketing withdrawals of obesity drugs.³¹

That history is exactly why the FDA now requires cardiovascular outcome trials for obesity drugs before or shortly after approval, and why researchers and regulators are watching the current crop so carefully. The GLP-1 drugs have cleared a higher bar of evidence than any previous generation of weight loss medication, but vigilance is earned, not assumed. Animal studies flagged a theoretical thyroid cancer risk with GLP-1 drugs (thyroid C-cell tumors in rodents), and while that has not materialized in human data so far, it is why these drugs carry a boxed warning and are contraindicated in people with certain thyroid cancer histories.

Effects on the Gut Microbiome

An area of active curiosity is how these drugs reshape the community of bacteria in the gut. Animal research has shown that liraglutide substantially altered the overall structure of the gut microbiome, shifting it toward a profile more commonly seen in lean animals. A different diabetes drug that does not act through GLP-1 receptors did not produce the same shift, suggesting the effect is tied to the GLP-1 pathway rather than just weight loss itself.³² How much this matters for human patients is still unclear. Whether a “leaner” microbiome profile contributes to the drug’s benefits or is simply a downstream consequence of eating less and losing weight is a question researchers are still working out. It is worth watching because gut bacteria influence everything from inflammation to appetite signaling, but it is too early to draw practical conclusions from it.